BR112012026016A2 - combinação de um inibidor macrocíclico de hcv, um não-nucleosídeo e um nucleosídeo - Google Patents

combinação de um inibidor macrocíclico de hcv, um não-nucleosídeo e um nucleosídeo

Info

Publication number
BR112012026016A2
BR112012026016A2 BR112012026016A BR112012026016A BR112012026016A2 BR 112012026016 A2 BR112012026016 A2 BR 112012026016A2 BR 112012026016 A BR112012026016 A BR 112012026016A BR 112012026016 A BR112012026016 A BR 112012026016A BR 112012026016 A2 BR112012026016 A2 BR 112012026016A2
Authority
BR
Brazil
Prior art keywords
nucleoside
combination
macrocyclic
hcv inhibitor
inhibitor
Prior art date
Application number
BR112012026016A
Other languages
English (en)
Inventor
Oliver Lenz
Pierre Jean-Marie Bernard Raboisson
Tse-I Lin
Original Assignee
Janssen Pharmaceuticals Inc
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Medivir Ab filed Critical Janssen Pharmaceuticals Inc
Publication of BR112012026016A2 publication Critical patent/BR112012026016A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

combinação de um inibidor macrocíclico de hcv, um não-nucleosídeo e um nucleosídeo. a presente invenção refere-se a uma combinação de um inibidor de hcv protease macrocíciclo, um inibidor de hcv polimerase de não-nucleosídeo macrocíclico e um inibidor de hcv polimerase de nucleosídeo.
BR112012026016A 2010-04-13 2011-04-13 combinação de um inibidor macrocíclico de hcv, um não-nucleosídeo e um nucleosídeo BR112012026016A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10159825 2010-04-13
PCT/EP2011/055836 WO2011128378A1 (en) 2010-04-13 2011-04-13 Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside

Publications (1)

Publication Number Publication Date
BR112012026016A2 true BR112012026016A2 (pt) 2016-06-07

Family

ID=42237337

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026016A BR112012026016A2 (pt) 2010-04-13 2011-04-13 combinação de um inibidor macrocíclico de hcv, um não-nucleosídeo e um nucleosídeo

Country Status (14)

Country Link
US (1) US20130028865A1 (pt)
EP (1) EP2558091A1 (pt)
JP (1) JP5989635B2 (pt)
KR (1) KR20130057990A (pt)
CN (1) CN102844028B (pt)
AU (1) AU2011239974B2 (pt)
BR (1) BR112012026016A2 (pt)
CA (1) CA2796243A1 (pt)
EA (1) EA201291042A1 (pt)
HK (1) HK1180222A1 (pt)
MX (1) MX2012011963A (pt)
NZ (1) NZ602552A (pt)
SG (2) SG10201506652QA (pt)
WO (1) WO2011128378A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
CN104780921A (zh) * 2012-08-31 2015-07-15 杨森制药公司 Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2552319C (en) 2004-01-30 2012-08-21 Medivir Ab Hcv ns-3 serine protease inhibitors
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
KR20090078347A (ko) 2006-10-10 2009-07-17 메디비르 아베 Ｈｃｖ 뉴클레오시드 억제제
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
AR077125A1 (es) * 2009-06-23 2011-08-03 Gilead Sciences Inc Combinaciones farmaceuticas utiles para tratar el vhc

Also Published As

Publication number Publication date
MX2012011963A (es) 2012-12-17
JP2013523866A (ja) 2013-06-17
NZ602552A (en) 2014-09-26
CA2796243A1 (en) 2011-10-20
US20130028865A1 (en) 2013-01-31
EP2558091A1 (en) 2013-02-20
KR20130057990A (ko) 2013-06-03
SG10201506652QA (en) 2015-10-29
AU2011239974A1 (en) 2012-10-25
AU2011239974B2 (en) 2015-12-03
JP5989635B2 (ja) 2016-09-07
EA201291042A1 (ru) 2013-03-29
SG184524A1 (en) 2012-11-29
WO2011128378A1 (en) 2011-10-20
CN102844028B (zh) 2016-04-06
HK1180222A1 (zh) 2013-10-18
CN102844028A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY34851A (es) Inhibidores macrocíclicos de virus flaviviridae
CR11202S (es) Botella
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CR20110143S (es) Stent quirúrgico
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CR20110141S (es) Montaje de stent quirurgico
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
UY33504A (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
BR112013003536A2 (pt) composição, e utilização de uma composição.
BR112012019182A2 (pt) placa de cimento leve.
CR20120425S (es) Unidad de puente de concreto
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
CR20120372S (es) Enfriador
BR112012026016A2 (pt) combinação de um inibidor macrocíclico de hcv, um não-nucleosídeo e um nucleosídeo
TWD166471S (zh) 手錶
UA111663C2 (uk) Газопродувний елемент і співвіднесений газопідвідний трубопровід
EA201391563A1 (ru) Твердое вещество полихлоропрен с тиксотропными свойствами
BR112015003913A2 (pt) combinação de inibidor macrocíclico da protease do hcv, inibidor do hcv não nucleosídeo e ritonavir
BR112013000930A2 (pt) formulações de 14-epi-análogos de vitamina d e cmc
HN2009003469A (es) Biscocho lleno
UY33207A (es) Métodos de preparación de tiazolidinas
UA72478U (ru) Применение полентара как средства фригопротекторного действия
AU343486S (en) Flashlight
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]